Thursday, the EU contracted with Pfizer and Moderna to purchase 350 million more doses of their SARS-CoV-2 vaccines, making for 2.6 billion doses in the pipeline altogether. Between those two and CureVac, this means mRNA vaccines account for 1.465 billion doses:
| Technology | Manufacturer(s) | Number of Doses (Millions) | % of total |
|---|---|---|---|
| mRNA | Pfizer/BioNTech, Moderna, CureVac | 1,465 | 54% |
| Vectored Virus | AstraZeneca, Johnson & Johnson | 800 | 29% |
| Protein Subunit | Sanofi GSK | 300 | 11% |
Sanofi earlier this week reported they would not have a COVID-19 subunit vaccine ready this year, so this purchase looks like the plugging of a hole rather than an increase. More importantly, it seems to me that if Peter Hotez is right as to what types of vaccines are going to be the "the workhorse of this epidemic", it is getting awfully late for any technology other than mRNA.
Update: it's probably worth mentioning that once you subtract the 300M vaccines Sanofi can't deliver, suddenly mRNA has 61% of EU sales. That's quite a vote of confidence.
No comments:
Post a Comment